Response to comments on the Scientific Opinion of the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on the modification of the authorisation of a health claim related to plant sterol esters and lowering blood LDL-cholesterol; high blood LDL-cholesterol is a risk factor in the development of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006, following a request in accordance with Article 19 of Regulation (EC) No 1924/2006

Question Number
EFSA-Q-2014-00310
Issued
20 May 2014
Abstract

Following a request from the European Commission, EFSA was asked to address the scientific comments received on the Scientific Opinion of the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on the modification of the authorisation of a health claim related to plant sterol esters and lowering blood LDL-cholesterol; high blood LDL-cholesterol is a risk factor in the development of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006, following a request in accordance with Article 19 of Regulation (EC) No 1924/2006. Comments submitted to EFSA via the European Commission Services originated from the applicant (SANOFI-AVENTIS FRANCE). The comments received were related to the scientific evaluation of the Panel on the extension of the conditions of use to plant sterol esters in powder. EFSA has reviewed and shared these comments with the chair of the NDA Panel and the chair of the NDA Working Group on Claims. The comments received do not require any change to the conclusions of the NDA Panel.

Published in the EFSA Journal
21 May 2014